The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Liposomal Drug Delivery Devices Market?
The liposomal drug delivery devices market has experienced rapid expansion in recent years. It is anticipated to grow from $5.34 billion in 2025 to $6.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.4%. The increase observed in the historic period is attributable to advancements in nanotechnology-based drug delivery, increasing cancer prevalence, expansion of injectable drug formulations, rising use of liposomal antifungal therapies, and growing pharmaceutical research investments.
The liposomal drug delivery devices market size is anticipated to undergo significant expansion over the next few years. It is projected to climb to $9.49 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.1%. This growth during the forecast period is propelled by factors including the escalating demand for targeted cancer treatments, the broadening application of personalized medicine approaches, an increased uptake of advanced drug delivery platforms, growing investments in biologics and vaccines, and a heightened focus on reducing drug toxicity. Prominent trends throughout this period encompass the increasing adoption of targeted drug delivery systems, the rising application of pegylated liposomal formulations, expanding usage in oncology therapies, the wider development of liposomal vaccines and antifungals, and an intensified focus on achieving controlled drug release.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3349&type=smp
Which Major Factors Are Contributing To The Development Of The Liposomal Drug Delivery Devices Market?
The global increase in cancer cases is anticipated to drive the expansion of the liposomal drug delivery devices market moving forward. Cancer encompasses a broad spectrum of diseases characterized by the unchecked proliferation and spread of abnormal cells; its escalating incidence is attributed to a combination of population aging, environmental hazards, and shifts in lifestyle. As the prevalence of cancer grows, there is an heightened demand for advanced, targeted therapies, such as liposomal formulations, which can enhance drug delivery, mitigate systemic toxicity, and boost treatment efficacy. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 20 million new cancer cases occurred in 2022, with projections indicating this number will reach 35 million by 2050, representing a 77% increase. Thus, the growing worldwide burden of cancer is a significant catalyst for the growth of the liposomal drug delivery devices market.
What Segment Categories Are Evaluated In The Liposomal Drug Delivery Devices Market Study?
The liposomal drug delivery devices market covered in this report is segmented –
1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types
2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users
Subsegments:
1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin
2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel
3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B
4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine
What Trends Are Affecting The Growth Of The Liposomal Drug Delivery Devices Market?
Leading firms in the liposomal drug delivery sector are launching cutting-edge products, like hydrochloride liposome injection, to enhance their market competitiveness. Research efforts have focused on creating liposomal nanostructures capable of boosting patient adherence by enabling less frequent dosing without compromising effectiveness. As an example, in August 2024, Lupin Ltd., an Indian pharmaceutical enterprise, introduced Doxorubicin Hydrochloride Liposome Injection in concentrations of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). This Doxorubicin Hydrochloride Liposome Injection recorded estimated annual sales of around USD 40.9 million in the U.S. market by June 2024. This move strategically positions Lupin within the oncology segment, broadening its product portfolio with a vital cancer treatment. The launch underscores Lupin’s dedication to improving patient health, aiming to offer effective therapeutic alternatives within a competitive pharmaceutical environment.
Who Are The Major Companies Operating In The Liposomal Drug Delivery Devices Market?
Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company
Access The Complete Liposomal Drug Delivery Devices Market Report:
What Is The Largest Regional Market In The Liposomal Drug Delivery Devices Market?
North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Liposomal Drug Delivery Devices Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Liposomal Drug Delivery Devices Market 2026, By The Business Research Company
Liposuction Surgery Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/liposuction-surgery-devices-global-market-report
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Liposomal Doxorubicin Market Report 2026
https://www.thebusinessresearchcompany.com/report/liposomal-doxorubicin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model